Dexpramipexole dihydrochloride Catalog No.:M9926-2 ZLN024 directly activates recombinant AMPK

ZLN024 directly activates recombinant AMPK α1β1γ1 and its homologue α2β1γ1 in a concentration-dependent manner

2017 Jan 6

Ginsenoside Rb2 enhances the anti-inflammatory effect of ω-3 fatty acid in LPS-stimulated RAW264

7Sodium Channel inhibitor1 demonstrated concentration-dependent efficacy in preclinical behavioral pain models

which shows significant inhibitory activity towards LTA4 hydrolase with IC50 of 8 nM

Dexpramipexole dihydrochloride Catalog No.:M9926-2 ZLN024 directly activates recombinant AMPKDexpramipexole, also known as KNS 760704 and (R) Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well